Tarayyar Turai ta amince da kwayar COVID-19 ta farko
Tarayyar Turai ta amince da kwayar COVID-19 ta farko

The European Medicines Agency (EMA) has announced that it has issued the conditional authorization (CMA) for Pfizer’s oral coronavirus treatment, Paxlovid.

A cikin ci gaba da yaduwar kwayar cutar omicron damuwa a ciki Turai, EMA ta ce an ba da shawarar kwayar cutar coronavirus ta farko "don kula da COVID-19 a cikin manya waɗanda ba sa buƙatar ƙarin iskar oxygen kuma waɗanda ke cikin haɗarin cutar ta zama mai tsanani."

Hanyar CMA, in ji EMA, ana amfani da ita don hanzarta aiwatar da izini na magunguna "a lokacin larurar lafiyar jama'a."

Tare da amincewar hukumar Turai. Paxlovid ya zama maganin rigakafi na farko da ake bayarwa ta baki wanda aka ba da shawarar a cikin EU don magance COVID-19.

Yarda da Paxlovid follows the authorization in December of antibody treatment Xevudy, produced by GlaxoSmithKline and Vir Biotechnology, as well as Kineret by Swedish Sobi, which was originally an arthritis drug but is able to “reduce” COVID-related inflammation.

Paxlovid's fafatawa a gasa, Merck's Lagevrio (molnupiravir), ya kasance a karkashin la'akari da EMA, kamar yadda tasiri ya tabbatar da zama kasa fiye da sa ran.

Duk Paxlovid da molnupiravir sun sami izini daga Hukumar Kula da Abinci da Magunguna ta Amurka a cikin Disambar bara.

 

Print Friendly, PDF & Email

Shafin Farko